HTGMQ (HTG Molecular Diagnostics) EBIT: $-19.39 Mil (TTM As of Mar. 2023)


HTGMQ HTG Molecular Diagnostics Inc HTGMQ
12 GF Score
Price $0.00
View Full Analysis

What is HTG Molecular Diagnostics EBIT?

HTG Molecular Diagnostics HTGMQ 12 EBIT is $-19.39 Mil as of Mar. 2023. GuruFocus rates HTGMQ with a GF Score™ of 12/100.

HTG Molecular Diagnostics's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2023 was $-4.91 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2023 was $-19.39 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. HTG Molecular Diagnostics's annualized ROC % for the quarter that ended in Mar. 2023 was -296.74%. HTG Molecular Diagnostics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2023 was -1,299.14%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.


HTG Molecular Diagnostics  (OTCPK:HTGMQ) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

HTG Molecular Diagnostics's annualized ROC % for the quarter that ended in Mar. 2023 is calculated as:

ROC % (Q: Mar. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2022 ) + Invested Capital (Q: Mar. 2023 ))/ count )
=-20.052 * ( 1 - 0% )/( (7.031 + 6.484)/ 2 )
=-20.052/6.7575
=-296.74 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

HTG Molecular Diagnostics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2022  Q: Mar. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-19.656/( ( (1.605 + max(-0.543, 0)) + (1.421 + max(-0.378, 0)) )/ 2 )
=-19.656/( ( 1.605 + 1.421 )/ 2 )
=-19.656/1.513
=-1,299.14 %

where Working Capital is:

Working Capital(Q: Dec. 2022 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1.422 + 0.909 + 1.109) - (3.367 + 0 + 0.616)
=-0.543

Working Capital(Q: Mar. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1.132 + 0.655 + 0.837) - (1.754 + 0 + 1.248)
=-0.378

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

HTG Molecular Diagnostics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2023 )
=-19.393/0.000
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


HTG Molecular Diagnostics EBIT Related Terms


HTG Molecular Diagnostics EBIT Historical Data

* Premium members only.

The historical data trend for HTG Molecular Diagnostics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HTG Molecular Diagnostics EBIT Chart

HTG Molecular Diagnostics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -15.55 -18.34 -19.83 -16.06 -20.73

HTG Molecular Diagnostics Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.25 -5.65 -4.31 -4.52 -4.91

HTGMQ vs ABMC, TMO, DHR: EBIT Comparison

For the Diagnostics & Research subindustry, HTG Molecular Diagnostics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HTG Molecular Diagnostics EV-to-EBIT vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, HTG Molecular Diagnostics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where HTG Molecular Diagnostics's EV-to-EBIT falls into.


HTGMQ
12GF Score
HTG Molecular Diagnostics Inc HTGMQ
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HTG Molecular Diagnostics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-19.39 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-19.39 Mil mean?
HTG Molecular Diagnostics (HTGMQ) has a EBIT of $-19.39 Mil as of Mar. 2023. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on HTG Molecular Diagnostics.
Is HTG Molecular Diagnostics' EBIT too high?
HTG Molecular Diagnostics' current EBIT is $-19.39 Mil. Overall, HTG Molecular Diagnostics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does HTG Molecular Diagnostics' EBIT compare to ABMC and TMO?
HTG Molecular Diagnostics' EBIT of $-19.39 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Diagnostics & Research company?
A good EBIT depends on the Medical Diagnostics & Research industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on HTG Molecular Diagnostics. HTG Molecular Diagnostics's current EBIT is $-19.39 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HTG Molecular Diagnostics stock overvalued right now?
HTG Molecular Diagnostics (HTGMQ) has a current EBIT of $-19.39 Mil. The current EBIT is $-19.39 Mil. HTG Molecular Diagnostics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For HTG Molecular Diagnostics (HTGMQ), the current EBIT is $-19.39 Mil as of Mar. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

HTG Molecular Diagnostics Business Description

Address 3430 E. Global Loop, Tucson, AZ, USA, 85706
HTG Molecular Diagnostics Inc is a life science company whose mission is to advance precision medicine through its transcriptome-wide profiling and medicinal chemistry technologies. The company derives revenue from sales of its HTG EdgeSeq system and integrated next-generation sequencing-based HTG EdgeSeq research use only assays and from sample processing services performed in its VERI/O laboratory. The company operates in one segment and its customers and distributors are located in the United States and Europe.
12GF Score

Get the complete analysis for HTGMQ

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price